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Abstract
Background: Qianggu Capsule, a Chinese patent medicine, has been widely applied in the clinical practice of
primary osteoporosis (POP) in recent years. This study aims to summarize the effectiveness and safety of Qianggu
Capsule in treating POP.
Methods: We searched seven electronic databases, all searches ended in 30 September, 2015. All randomised
controlled trials comparing the efficacy of Qianggu Capsule treatment with no treatment, placebo or conventional
therapy for POP were included. Combined therapies of Qianggu Capsule were also included. Cochrane risk of bias tool
was used to assess methodological quality of primary studies. Revman 5.2.0 software was used for data analysis.
Results: Ten trials were enrolled. The combined effect showed that Qianggu Capsule plus Caltrate D was better than
Caltrate D on lumbar spine bone mineral density (BMD) (MD = 0.05 g/cm2; 95% CI: 0.02–0.07; P = 0.0004), femoral neck
BMD (MD = 0.03 g/cm2; 95% CI: 0.01–0.05; P = 0.001), femoral great trochanter BMD (MD = 0.04 g/cm2; 95% CI: 0.03–0.
06; P < 0.001). Meta-analysis exhibited a significant antiosteoporosis effect of Qianggu Capsule on femoral neck BMD
(MD = 0.03 g/cm2; 95% CI: 0.01–0.05; P = 0.003) and femoral trochanteric BMD (MD = 0.07 g/cm2; 95% CI: 0.02–0.12; P =
0.006) compared with α-D3 capsule. However, the methodological quality of included studies was low. Constipation
and dry mouth were the most common adverse drug reactions of Qianggu Capsule. Finally the evidence level was
evaluated to be low or very low.
Conclusions: The effect of Qianggu Capsule for POP was supported in improving BMD. Due to the methodological
drawbacks of the included studies, the conclusions should be treated with caution for future research.
Keywords: Qianggu Capsule, Primary osteoporosis, Chinese patent medicine, Systematic review
Background
Primary osteoporosis (POP) is one of the most common
chronic conditions, and affects both old men and post-
menopausal women [1, 2]. Osteoporosis is estimated to
cause 1.5 million fractures every year in the United
States [3]. In China, there have been about 202.43
million people aged 60 years and older at the end of
2013, which faces higher risk of osteoporosis-related
fractures [4]. From 2002 to 2006, the rates of hip frac-
ture over age 50 years have increased 58% in women
and 49% in men based on a population-based study in
Beijing [5]. Most important of all, the most serious con-
sequences of osteoporotic fractures, especially hip frac-
ture, are the increasing proportion of mortality and
disability [6]. Therefore, interventions to treat POP or
prevent osteoporotic fractures should be implemented.
Although research efforts have been expanded for
several decades, an urgent need exists for continued im-
provement so far, particularly in the treatment of POP.
Many strategies are available to treat POP, but pharma-
cological treatments still plays the dominant role. Major
antiosteoporosis agents including bisphosphonates, deno-
sumab, hormone replacement therapy, selective estrogen
receptor modulators, recombinant human parathyroid
hormone and strontium ranelate are currently available
on the market [7]. The common outcomes are
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osteoporotic fractures [8, 9], bone mineral density (BMD)
value [10], bone turnover markers [11], pain assessment
[12], quality of life [13], and adverse event or adverse drug
reaction mainly from antiosteoporosis drugs [14]. In some
cases, POP patients can benefit from drug therapy
optimization and combination therapy. Despite the fact
that several western medicines have demonstrated to be
effective in the treatment of POP, however, poor medica-
tion adherence remains a major problem [15, 16]. Sub-
optimal adherence to therapy may partially be due to
adverse effects of long-term conventional antiosteoporosis
drugs, such as bisphosphonates [17, 18]. Hence, there is a
requirement for long-term treatment to be associated with a
positive benefit-risk balance [19]. Now more and more stud-
ies of complementary and alternative medicine have in-
creased the awareness of the problem and have improved
our understanding of the prevention and control of osteo-
porosis. In China, herbal fufang and single Chinese herb
have been widely used for the treatment of POP [20–22].
Qianggu Capsule, the main effective components of which
are the total flavonoids of Rhizoma Drynariae (Gusuibu)
[23], has been approved by China Food and Drug Adminis-
tration for treating POP (drug approval numbers:
Z20030007). According to the theory of traditional Chinese
medicine and results of population pharmacokinetics,
Qianggu Capsule has the effect of replenishing the kidney
and strengthening the bones which applies to shen-yang de-
ficiency pattern [24, 25]. Modern research has also proven
that Qianggu Capsule can increase lumbar and femoral
BMD, raise serum calcium, improve analgesia action, con-
trol the levels of serum IL-6 and TNFa, and accelerate the
secretion of IL-4 in rats. No abnormal changes are found in
the toxicity test [26]. So Qianggu Capsule is reliable and safe
in laboratory studies.
In contrast to the wealth of data about the efficacy of
chemical agents in the management of POP, information
regarding their efficacy and safety in Chinese herbal
medicine is relatively limited. In recent years, a large
number of clinical studies reported the effect of Qianggu
Capsule and Qianggu Capsule combined with antiosteo-
porosis drugs. Therefore, this systematic review provides
an evidence of Qianggu Capsule for the management of
POP from the randomised controlled trials.
Methods
The study protocol was previously registered in
PROSPERO platform which could be available on
https://www.crd.york.ac.uk/PROSPERO/display_recor-
d.asp?ID=CRD42015025784.
Data sources and searches
Seven electronic databases were searched from their in-
ception until 30 September, 2015: PubMed, Cochrane
CENTRAL, EMBASE, Chinese National Knowledge
Infrastructure (CNKI), Wanfang database, Chinese
Scientific Journals Database (VIP), Chinese Biomedical
Literature Database (CBM). Additional published or un-
published literature was retrieved through manual
searches of reference lists of included studies and key re-
view articles, and from the files of content experts.
The search terms included “osteoporosis”, “primary
osteoporosis”, “senile osteoporosis”, “postmenopausal
osteoporosis”, “qianggu capsule”, “qiang gu capsule” and
“Gusuibu”. Search terms used for PubMed were as fol-
lows: (osteoporosis OR primary osteoporosis OR senile
osteoporosis OR postmenopausal osteoporosis) AND
(qianggu capsule OR qiang gu capsule OR Gusuibu).
Types of studies
All completed randomised controlled trials comparing
the efficacy of Qianggu Capsule treatment for POP were
enrolled. Animal experiments were not inclusive.
Types of participants
The clinical diagnosis was required to be in accordance
with the criteria of POP. It should be noted that some
minor differences existed among different diagnostic cri-
teria. For example, World Health Organization criteria
(BMD of subjects, 2.5 SD [T-score < or = −2.5] lower
than young adult mean value) [27] had a different nu-
merical standard than that for Chinese criteria (BMD of
subjects, 2 SD [T-score < or = −2] or less than 75% of
lower than young adult mean value) [28, 29]. Generally,
study population was mainly from middle-aged and aged
people (≥40 years).
Types of interventions
In this review, randomised controlled trials that assessed
the therapeutic effect of Qianggu Capsule, compared with
no treatment, placebo or conventional therapy were con-
sidered. Combined therapies of Qianggu Capsule and
other conventional interventions compared with other
conventional interventions in randomised controlled trials
were also enrolled. The interventions containing other
complementary and alternative treatments (Chinese medi-
cine, acupuncture, moxibustion, massage, yoga, tai chi, qi-
gong, baduanjin, wuqinxi and so on) in the Qianggu
Capsule or comparison group were excluded. The dur-
ation of treatment was required to be at least 3 months.
Types of outcomes
The primary outcome was osteoporosis-related fractures.
The secondary outcomes analyzed in this review were
BMD values, pain scores, quality of life, biochemical
markers of bone turnover, and adverse event or adverse
drug reaction (ADR).
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Study selection
Two reviewers independently searched and screened the
studies. Exclusion criteria included: (1) inappropriate study
design, such as reviews, case reports, comments, letters; (2)
duplicate trials; (3) not population of interest; (4) no
Qianggu Capsule intervention; (5) lack of the above out-
comes. After removing excluded abstracts, full articles were
obtained and studies were screened again more thoroughly
using the same exclusion criteria. Any disagreements were
resolved through discussion with a third reviewer.
Data abstraction
Data abstraction was independently performed by two
reviewers based on pre-piloted forms. A neutral third
reviewer was consulted if there are still disagreements
after discussion. The first author names and year of
publication, sample size, diagnostic criteria, population
characteristics (age and sex), duration of symptom, inter-
vention details (medication doses, therapeutic regimen
and treatment duration), and outcome data were
extracted.
Risk of bias assessment in individual studies
We used the Cochrane risk of bias tool to assess meth-
odological quality of included studies [30]. And two au-
thors compared the evaluation results and discussed
difference until agreement was reached. Selection bias,
performance bias, detection bias, attrition bias, reporting
bias and other bias were evaluated respectively. The qual-
ity of included trials was divided into three levels: low risk
of bias (all the items were in low risk of bias), high risk of
bias (at least one item was in high risk of bias), unclear
risk of bias (at least one item was in unclear).
Analytical approach
Data analysis was performed with Review Manager 5.2.0
software. Based on the continuous data, mean difference
(MD) was used to assess the difference between experi-
mental group and control group. Standardized mean dif-
ference (SMD) was considered if clinical outcome was
the same but measured using different scales in the dif-
ferent trials. Risk ratio (RR) was used for the binary data.
And the 95% confidence intervals (CI) were calculated
Fig. 1 PRISMA flowchart
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in the meta-analysis. In a three-group design study that
had two treatment groups of Qianggu Capsule and
Qianggu Capsule plus antiosteoporosis drugs, the two
comparisons were split in the meta-analysis. Heterogen-
eity was assessed by means of I2 statistic. If the I2 statis-
tic indicated considerable heterogeneity (≥50%), we
combined the summary measures across the studies
using a random effects model that assumed that the in-
cluded studies represent a sample from a larger popula-
tion of studies [31]. Analysis of subgroups will be used if
there are sufficient clinical trials for the same outcome.
Qualitative analysis of trial results
We evaluated the quality of the body of evidence adopt-
ing the GRADE approach [32, 33]. High quality evidence
was considered as randomised controlled trials with low
risk of bias that produced consistent, direct and precise
results for the clinical outcome [34]. Three domains, in-
cluding large magnitude of effect, all plausible confound-
ing which can increase confidence in estimated effects,
high dose–response gradient may increase the quality of
evidence [35, 36]. Levels of quality of evidence were de-
fined as high, moderate, low, very low [37].
Results
Characteristics of the studies
The search strategy identified 332 reports. After removal
of duplicates, 220 records remained. After going through
the titles and abstracts, 192 reports were excluded with at
least one of following reasons: (1) animal experiments; (2)
traditional review or not from POP patients; (3) lack of
control group. Then the remaining 28 papers were further
assessed with accessible full text. Eventually 10 reports
[38–47] met the inclusion criteria for the review and 18
papers were excluded. The reasons for exclusion were:
non-RCTs (n = 8), inappropriate intervention (n = 10). The
screening process was showed in a PRISMA 2009 flow
diagram (Fig. 1). All the studies were published in Chinese
journals (from 2004 to 2013).
Of the 10 articles, 806 participants were enrolled in the
review and depicted in Table 1. Eight trials used Chinese
osteoporosis diagnostic criteria [38, 40–42, 44–47]. Two
trials were also included because BMD was used for the
diagnosis and evaluation [39, 43]. The average age ranged
from 57.9 to 70.4 years. Course of disease was provided in
only 2 trials [41, 47] and was not found in the remaining
included studies.
To reduce the clinical heterogeneity among the stud-
ies, the interventions could be divided into 7 different
subgroups as follows: (1) Qianggu Capsule versus
Calcium gluconate [38]; (2) Qianggu Capsule versus
Livial [39]; (3) Qianggu Capsule plus Caltrate D versus
Caltrate D [40, 47]; (4) Qianggu Capsule versus Vitamin
D2 and calcium hydrogen phosphate tablets [41]; (5)
Qianggu Capsule versus α-D3 capsule [42, 43, 45]; (6)
Qianggu Capsule and Calcium tablet versus Qianggu
Capsule placebo and Calcium tablet [44]; (7) Qianggu
Capsule plus Alendronate versus Alendronate [46]. The
duration of treatment was not beyond 12 months.
All the studies reported different parts of BMD values
[38–47]. Three studies used bone biochemical markers as
surrogate outcome [42–44]. Seven studies reported adverse
drug reaction (ADR) [38–40, 42, 43, 45, 46]. In addition,
osteoporotic fractures, internationally recognized pain scales
and quality of life were not evaluated in all trials.
Quality of methodological reporting
The methodological quality of primary studies was
evaluated as low (as shown in Table 2). Only 1 trial
reported random number table as the method of
randomization [46]. A randomized, double-blind and
placebo-controlled trial was identified [44]. Allocation
concealment, blinding of participants and personnel
were not found in the other studies. The blinding of
outcome assessment was not stated in all trials. Two
Fig. 2 Meta-analysis of Qianggu Capsule plus Caltrate D versus Caltrate D on lumbar spine BMD
Fig. 3 Meta-analysis of Qianggu Capsule plus Caltrate D versus Caltrate D on femoral neck BMD
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trials did not provide any information about the drop-outs
or withdrawals [40, 44]. None of the trials registered or
published the study protocol. So the selective reporting
was unclear. Additionally, other sources of bias were iden-
tified as unclear in 3 trials because the baseline of the tri-
als was not mentioned [38, 41, 44].
Effect of the interventions
All the included studies compared Qianggu Capsule
practised alone or combined with antiosteoporosis
drugs. According to the different intervention and con-
trol program, the interventions could be divided into the
following subgroups.
1. Qianggu Capsule versus Calcium gluconate: there
was a statistically significant difference between the
groups in mean improvement on lumbar BMD
favoring Qianggu Capsule intervention after 3 months
(P < 0.05) [38].
2. Qianggu Capsule versus Livial: BMD in lumbar
spine and femoral neck increased markedly in livial
group, but statistical significance was not found in both
groups after 6 months (P > 0.05) [39].
3. Qianggu Capsule plus Caltrate D versus Caltrate D:
The combined analysis of two trials found a significant
effect of Qianggu Capsule plus Caltrate D on lumbar
spine BMD (MD = 0.05 g/cm2; 95% CI: 0.02–0.07; P =
0.0004, Fig. 2), femoral neck BMD (MD = 0.03 g/cm2;
95% CI: 0.01–0.05; P = 0.001, Fig. 3), femoral great
trochanter BMD (MD = 0.04 g/cm2; 95% CI: 0.03–0.06;
P < 0.001, Fig. 4) [40, 47]. In addition, there was no sig-
nificant difference on ward’s BMD between the groups
in the result of Xia et al. (P < 0.05) [40].
4. Qianggu Capsule versus Vitamin D2 and calcium
hydrogen phosphate tablets: Qianggu Capsule group
demonstrated a significant improvement on BMD of
ulna and radius compared with Vitamin D2 and calcium
hydrogen phosphate tablets group after 3 months (P <
0.05) [41].
5. Qianggu Capsule versus α-D3 capsule: There was
no significant difference on lumbar spine BMD (MD
= 0.05 g/cm2; 95% CI: −0.01–0.11; P = 0.09, Fig. 5) be-
tween the groups [42, 43, 45]. Meta-analysis indicated
a significant antiosteoporosis effect of Qianggu
Capsule on femoral neck BMD (MD = 0.03 g/cm2;
95% CI: 0.01–0.05; P = 0.003, Fig. 6) [42, 43, 45], fem-
oral trochanteric BMD (MD = 0.07 g/cm2; 95% CI:
0.02–0.12; P = 0.006, Fig. 7) compared withα-D3 cap-
sule [42, 45]. A remarkable improvement in ward’s
BMD with Qianggu Capsule was identified in Gao’s
study (P < 0.01) [45].
Meta-analysis of two trials showed that there was no
difference in improving the level of calcium (MD =
0.01 mmol/L; 95% CI: −0.04–0.06; P = 0.69), phosphorus
(MD = 0.01 mmol/L; 95% CI: −0.04–0.06; P = 0.67) and
alkaline phosphatase (MD = 3.05 U/L; 95% CI: −4.66–
10.76; P = 0.44) [42, 43]. In Wang’s study, Qianggu
Capsule was better thanα-D3 capsule in lowering NTX/
Cr (P < 0.01) [43].
6. Qianggu Capsule and Calcium tablet versus
Qianggu Capsule placebo and Calcium tablet: Based on
Calcium tablet as basic treatment, Qianggu Capsule was
better than placebo in improving lumbar BMD value
after 6 months (P < 0.01, P < 0.05). Qianggu Capsule plus
Calcium tablet also significantly increased the level of
bone gla protein, calcitonin and estradiol in the blood
(P < 0.01); on the other, the excretion of urinary hy-
droxyproline and the level of parathyroid hormone was
reduced (P < 0.01) [44].
7. Qianggu Capsule plus Alendronate versus Alendro-
nate: The BMD difference of lumbar spine and wards
area in combination therapy group was higher than
Alendronate group after 6 months (P < 0.01) [46].
Fig. 4 Meta-analysis of Qianggu Capsule plus Caltrate D versus Caltrate D on femoral great trochanter BMD
Fig. 5 Meta-analysis of Qianggu Capsule versus α-D3 capsule on lumbar spine BMD
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Adverse effects of Qianggu Capsule
Six trials reported ADRs of Qianggu Capsule used alone
[38–40, 42, 43, 45]. Three patients (3/41, 7.32%) with
constipation [38] and 2 patients (2/32, 6.25%) with mild
constipation [42] were found in Qianggu Capsule group.
Zhao et al. reported that 3 patients (3/34, 8.82%) with
constipation were identified in Qianggu Capsule group,
whereas 3 patients (3/35, 8.57%) with uncomfortable
hepatic region, 2 patients (2/35, 5.71%) with cutaneous
pruritus, and 3 patients (2/35, 5.71%) with colporrhagia
in livial group [39]. Xia et al. found that 2 patients (2/29,
6.90%) with constipation or dry mouth in Qianggu Cap-
sule group, 1 patient (1/29, 3.45%) with constipation in
the control group [40]. Similarly, Wang et al. reported 2
cases (2/28, 7.14%) with constipation and 1 case (1/28,
3.57%) with dry mouth in Qianggu Capsule group [43].
The study conducted by Gao et al. showed that 12 cases
(12/64, 18.75%) with mild constipation, 15 cases (15/64,
23.44%) with dry mouth, and 18 cases (18/64, 28.13%)
with lower rhythm of the heart in Qianggu Capsule
group, while 9 cases (9/64, 14.06%) with loss of appetite,
headache, vomit and 6 cases with higher blood calcium
levels in the control group [45]. Only 1 trial observed
the ADR of combination therapy [46]. The result dem-
onstrated that 6 cases (6/40, 15%) with nausea in com-
bination therapy group and 3 cases (3/40, 7.5%) with
nausea in Alendronate group.
All of the ADRs were not severe and relieved with-
out any treatment. Constipation and dry mouth were
the most common ADRs in the usage of Qianggu
Capsule.
Quality of evidence
Based on the GRADE approach, low quality evidence
(two trials, 208 participants) supported the Qianggu
Capsule plus Caltrate D in improving BMD compared
with Caltrate D; very quality evidence (three trials, 244
participants) supported the Qianggu Capsule in improv-
ing BMD compared withα-D3 capsule.
Discussion
Summary of the systematic review
More and more Chinese herbs have been historically used
to treat bone metabolic diseases and known for anti-
osteoporotic drugs [48–51]. The anti-osteoporosis effect
of Rhizoma Drynariae and its extracts have attracted
world-wide attention [52, 53]. Our systematic review is to
assess the efficacy and safety of Qianggu Capsule (Rhi-
zoma Drynariae) in osteoporosis therapy. The results of
meta-analysis suggested that Qianggu Capsule plus Cal-
trate D was more effective than Caltrate D alone on lum-
bar spine, femoral neck and femoral great trochanter
BMD [40, 47]. In addition, Qianggu Capsule had a more
significant effect on femoral neck and femoral trochan-
teric BMD compared withα-D3 capsule [42, 43, 45]. No
severe ADRs were found and the common ADRs could be
improved promptly without special treatment.
So far, there is only one systematic review reporting
Qianggu Capsule in treating POP [54]. Compared with
previously reported review, our study strictly followed
the PRISMA statement and added more randomised
controlled trials. Secondly, the control groups were lim-
ited to be no treatment, placebo or conventional therapy.
As well, for many complementary and alternative treat-
ments there were not enough information about their ef-
ficacy and safety. So the alternative interventions were
not enrolled as controls. Thirdly, we also summarized
and analyzed the objective quantized outcomes, includ-
ing bone formation and resorption markers.
Recommendation on the Efficacy evaluation of Qianggu
Capsule in the treatment of POP
In our study, definite conclusions could not be drawn in
some subgroups because of the limited trials [38, 39, 41,
Fig. 6 Meta-analysis of Qianggu Capsule versus α-D3 capsule on femoral neck BMD
Fig. 7 Meta-analysis of Qianggu Capsule versus α-D3 capsule on femoral trochanteric BMD
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44, 46]. The meta-analysis was performed according to
the homogeneity of the trials. Based on the current data,
osteoporotic-fractures, quality of life and the related
symptoms were not designed or evaluated in the in-
cluded trials. BMD and metabolic markers were the
most frequently reported outcomes. However, the results
of Meta-analysis across trials were hampered by the high
risk of bias, inconsistent result in some analysis, and
small sample sizes (<400) on the basis of the GRADE
approach. Eventually levels of quality of evidence were
evaluated as low or very low. Thus, interpretation of
these positive findings should be cautions.
On the other hand, the available meta-analysis did not
confirm the efficacy for biochemical markers of bone
turnover. The level of evidence was evaluated to be very
low. One possible reason was the small sample sizes and
short-term treatment. Meanwhile, some important bone
turnover markers were not used for the diagnosis or
evaluation in the primary studies. Accordingly, we suggest
that serum procollagen type I amino-terminal propeptide
(PINP) andβ-isomerised carboxy-terminal cross-linking
telopeptide of type I collagen (CTX) be used as one of the
important index, especially for the evaluation [55, 56].
Limitation of this systematic review and direction for
further clinical research
There are a number of methodological weaknesses in
the previous studies. The majority of the included trials
did not provide inadequate reporting of random method
and allocation concealment. Only 1 trial used placebo-
controlled design in our review [44]. Blinding is neces-
sary to avoid detection bias. Randomized clinical trials
without placebo design were likely to generate false posi-
tive results, such as the add-on design features (A + B
versus B) [57]. It is difficult to evaluate the Qianggu
Capsule absolute efficacy without a true placebo. Two
trials did not report information on drop-out and with-
draws [40, 44]. None of the included trials reported a
pretrial estimation of sample size. All the studies were
not large-scale randomized clinical trials. Since all the
trials were published in Chinese journals, we could not
exclude the potential publication bias.
Greater attention to methodological quality continues
to be needed. In the future, large-sample and high-
quality randomised, placebo-controlled trials should be
conducted to further confirm the efficacy of Qianggu
Capsule in treating POP. Since POP is a chronic meta-
bolic disease, the effect of long-term treatment is a great
concern of patients.
Conclusions
Qianggu Capsule alone or Qianggu Capsule plus Caltrate
D were beneficial for POP patients comparing to conven-
tional interventions in improving BMD. Nevertheless, the
evidence level was assessed to be low or very low accord-
ing to GRADE approach. Therefore, the interpretation of
that potential efficacy should be cautious, further research
with strictly designed method is needed. Adverse out-
comes of Qianggu Capsule mainly included constipation
and dry mouth.
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